--- title: "Candel Therapeutics (CADL) news: offering" url: "https://aibio.space/companies/candel-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CADL offering news: Candel Therapeutics agrees to sell about $15.0 million of stock in direct offering. Candel Therapeutics, Inc." --- CADL Candel Therapeutics, Inc. NASDAQ · United States # Candel Therapeutics (CADL) news CADL offering news Debt Financing · 2025-10-14 ## [Candel signs Trinity Capital term loan of up to $130.0 million, draws $50.0 million](https://aibio.space/news/candel-signs-trinity-capital-term-loan-up-130-0-million-draws-50-0/) Candel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million. ## Latest Candel Therapeutics news 1. 2025-06-24 Financings [Candel Therapeutics agrees to sell about $15.0 million of stock in direct offering](https://aibio.space/news/candel-therapeutics-agrees-sell-about-15-0-million-stock-direct/) Candel Therapeutics agreed on June 24, 2025 to sell 3,221,395 shares at $4.67 each in a registered direct offering. The prospectus names no placement agent or underwriter, and some buyers are directors and executive officers. ## Candel Therapeutics at a glance - **Ticker**: CADL - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $201.6 million ### Related companies - [Absci](https://aibio.space/companies/absci/) NASDAQ: ABSI - [LeonaBio](https://aibio.space/companies/leonabio/) NASDAQ: LONA - [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO - [Arcus Biosciences](https://aibio.space/companies/arcus-biosciences/) NYSE: RCUS - [Geron](https://aibio.space/companies/geron/) NASDAQ: GERN - [Aldeyra Therapeutics](https://aibio.space/companies/aldeyra-therapeutics/) NASDAQ: ALDX - [Intensity Therapeutics](https://aibio.space/companies/intensity-therapeutics/) NASDAQ: INTS - [Surrozen](https://aibio.space/companies/surrozen/) NASDAQ: SRZN ### Also on NASDAQ - [Bicara Therapeutics](https://aibio.space/companies/bicara-therapeutics/) BCAX - [Ionis Pharmaceuticals](https://aibio.space/companies/ionis-pharmaceuticals/) IONS - [Vivos Therapeutics](https://aibio.space/companies/vivos-therapeutics/) VVOS - [Corbus Pharmaceuticals Holdings](https://aibio.space/companies/corbus-pharmaceuticals/) CRBP - [NATURAL ALTERNATIVES INTERNATIONAL INC](https://aibio.space/companies/natural-alternatives-international/) NAII - [Tiziana Life Sciences](https://aibio.space/companies/tiziana-life-sciences/) TLSA ## Candel Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$30.5 million](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/) | [$19.3 million](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/) | | Net income (loss) | [-$38.2 million](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/) | [-$55.2 million](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/) | | Cash from operations | [-$38.3 million](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/) | [-$27.0 million](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/) | | Cash and equivalents | [$119.7 million](https://www.sec.gov/Archives/edgar/data/1841387/000119312526347980/) | [$102.7 million](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103134/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $201.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Candel Therapeutics Has Candel Therapeutics raised money recently? Our latest story on this, dated Jun 24, 2025: "Candel Therapeutics agrees to sell about $15.0 million of stock in direct offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/candel-therapeutics-agrees-sell-about-15-0-million-stock-direct/). What is the ticker symbol of Candel Therapeutics? Candel Therapeutics, Inc. trades under the ticker CADL on NASDAQ. Where is Candel Therapeutics listed? Candel Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Candel Therapeutics? The SEC Central Index Key (CIK) for Candel Therapeutics, Inc. is 1841387. Its filings are on SEC EDGAR. How many shares does Candel Therapeutics have outstanding? 76,518,565 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Candel Therapeutics listed under? Our directory records Candel Therapeutics, Inc. under United States. What does Candel Therapeutics do? Our directory classifies Candel Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Candel Therapeutics? The ISIN recorded for Candel Therapeutics, Inc. is US1374041093. Does aibio.space cover Candel Therapeutics? aibio.space lists Candel Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Candel Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Candel Therapeutics profitable? Candel Therapeutics, Inc. reported a net loss of $38.2 million for the fiscal year ended Dec 31, 2025, and used $38.3 million of cash in operations, per its annual report to the SEC. How much does Candel Therapeutics spend on research and development? $30.5 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Candel Therapeutics have? $201.6 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Candel Therapeutics (CADL) stock news? Our latest story on Candel Therapeutics, dated Oct 14, 2025: "Candel signs Trinity Capital term loan of up to $130.0 million, draws $50.0 million". Candel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million. [Source](https://aibio.space/news/candel-signs-trinity-capital-term-loan-up-130-0-million-draws-50-0/). Does Candel Therapeutics have debt, a term loan or convertible notes? Our latest debt story, dated Oct 14, 2025: "Candel signs Trinity Capital term loan of up to $130.0 million, draws $50.0 million". Candel signed a five-year term loan with Trinity Capital Inc. for up to $130 million and drew $50 million at closing. The loan carries a 10.25% initial rate, a 4.25% exit fee and a minimum cash covenant that applies if the company's market value falls below $550 million. [Source](https://aibio.space/news/candel-signs-trinity-capital-term-loan-up-130-0-million-draws-50-0/). ## Investor discussion: Candel Therapeutics Members talk about Candel Therapeutics (CADL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Candel Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-02-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1841387/000119312526059514/d116198d424b5.htm) 2. 2025-10-14 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.02,2.03,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1841387/000119312525238254/cadl-ex99_1.htm) 3. 2025-08-14 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1841387/000119312525180411/d121007ds3.htm) 4. 2025-06-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1841387/000119312525145401/d917630d424b5.htm) 5. 2024-12-12 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1841387/000119312524277171/d883046d424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CADL on TradingView](https://www.tradingview.com/symbols/NASDAQ-CADL/). ## SEC filings and registration - **SEC name**: Candel Therapeutics, Inc. - **CIK**: 1841387 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CADL (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 117 KENDRICK STREET, NEEDHAM, MA, 02494 - **Phone**: 617-916-5445 - **Shares outstanding**: 76,518,565 as of 2026-08-06 (10-Q filed 2026-08-13) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312526387310/cadl-20260906.htm) filed 2026-09-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312526386561/d738484d8k.htm) filed 2026-09-09 - [10-Q](https://www.sec.gov/Archives/edgar/data/1841387/000119312526347980/cadl-20260630.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312526347957/cadl-20260813.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1841387/000184138726000009/cadl-20260623.htm) filed 2026-06-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1841387/000184138726000007/cadl-20260612.htm) filed 2026-06-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1841387/000119312526226751/d106447d8k.htm) filed 2026-05-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1841387/000119312526222904/cadl-20260331.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001841387), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Candel Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CADL, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Candel Therapeutics, Inc. - **Ticker**: CADL - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US1374041093 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CADL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/candel-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Candel Therapeutics (CADL) news: offering", 2026-10-31, https://aibio.space/companies/candel-therapeutics/